Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups

Background COVID-19 vaccines approved in the UK are highly effective in general population cohorts, however, data on effectiveness amongst individuals with clinical conditions that place them at increased risk of severe disease are limited. Methods We used GP electronic health record data, sentinel...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitaker, Heather J., Tsang, Ruby S.M., Byford, Rachel, Andrews, Nick J., Sherlock, Julian, Sebastian Pillai, Praveen, Williams, John, Button, Elizabeth, Campbell, Helen, Sinnathamby, Mary, Victor, William, Anand, Sneha, Linley, Ezra, Hewson, Jacqueline, DArchangelo, Silvia, Otter, Ashley D., Ellis, Joanna, Hobbs, Richard F.D., Howsam, Gary, Zambon, Maria, Ramsay, Mary, Brown, Kevin E., de Lusignan, Simon, Amirthalingam, Gayatri, Lopez Bernal, Jamie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of The British Infection Association. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720678/
https://www.ncbi.nlm.nih.gov/pubmed/34990709
http://dx.doi.org/10.1016/j.jinf.2021.12.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720678/
https://www.ncbi.nlm.nih.gov/pubmed/34990709
http://dx.doi.org/10.1016/j.jinf.2021.12.044

Ejemplares similares